07:00 , Jun 14, 2004 |  BioCentury  |  Emerging Company Profile

Concurrent: The jump from computing

Until recently, Concurrent Pharmaceuticals Inc. has relied on its Concentric computational platform to identify and optimize small molecule candidates to treat cardiovascular and renal diseases. However, the company has taken a big step toward a...
08:00 , Mar 16, 1998 |  BC Week In Review  |  Company News

Allergan Specialty board of directors update

(Allergan distributes ASTI shares, B12; ASTI names CEO, see below) Allergan Specialty Therapeutics Inc. (ASTI), Irvine, Calif.   Business: Cancer, Neurological, Ophthalmic   Appointed: Alan Lewis, president and CEO of Signal Pharmaceuticals Inc. ; Gary...
08:00 , Dec 8, 1997 |  BC Week In Review  |  Company News

Allergan Ligand, Ligand, Allergan deal

LGND completed its purchase of the 3.25 million shares outstanding of ALRI at $21.97 per share (see BioCentury Extra, Sept. 25). LGND paid $7.69 in cash and 0.97 shares of LGND stock per share of...
07:00 , Sep 29, 1997 |  BC Week In Review  |  Company News

Allergan Ligand Retinoid Therapeutics Inc, Ligand Pharmaceuticals Inc, Allergan Inc deal

LGND and Allergan will buy back their ALRI joint venture. LGND will pay $71.4 million ($21.97 per share) and Allergan will pay LGND $8.9 million to acquire a one-half interest in the assets of ALRI...
07:00 , Sep 29, 1997 |  BioCentury  |  Finance

Raab promises blockbuster IPO

Ebb & Flow Raab promises blockbuster IPO Sinogen International, a Chinese manufacturer and distributor of alpha interferon, is looking to do an IPO next year, according to Chairman Kirk Raab, who warns investors to brace...
07:00 , Sep 8, 1997 |  BC Week In Review  |  Clinical News

Oral Panretin 9-cis-retinoic acid data

Researchers reported at the International Society of Hematology Conference in Stockholm that durable remissions have resulted from treatment in both newly diagnosed and relapsed patients with APL. A total of 4 of the 12 relapsed...
07:00 , Sep 2, 1997 |  BC Week In Review  |  Clinical News

Panretin 9-cis-retinoic acid topical gel data

Enrollment in a double-blind European Phase III trial in KS was stopped early after an interim analysis of 82 patients showed a complete or partial response in 42 percent of the Panretin group (15 of...
07:00 , Sep 2, 1997 |  BioCentury  |  Finance

When lightning strikes

Ebb & Flow One reason investors worry about the biotech sector is the magnitude of loss that can occur instantly on product setbacks. A reminder is...
07:00 , Jul 14, 1997 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Ligand Pharmaceuticals Inc. (LGND), San Diego, Calif. Business: Cancer Raymond James analyst Jacqueline Siegel said that she was disappointed that Panretin, an Allergan Ligand Retinoid Therapeutics (ALRI) compound, didn't show activity in non-Hodgkin's lymphoma (see...
07:00 , Jul 14, 1997 |  BC Week In Review  |  Clinical News

Oral Panretin 9-cis-retinoic acid: Phase II Update

Allergan Ligand Retinoid Therapeutics Inc. (ALRI), San Diego, Calif.   Product: Oral Panretin 9-cis-retinoic acid   Indication: Treat myelodysplastic syndrome (premalignancy of blood)   Status: Phase II testing is continuing, with 30 patients treated so...